Qureight, a Core Imaging Laboratory developing deep-learning image analytics, and Avalyn Pharma, a clinical-stage biopharmaceutical company focused on developing inhaled therapies to treat life-threatening pulmonary diseases, have entered into a strategic partnership that will focus on progressive pulmonary fibrosis.

As part of the agreement, Qureight’s s Core Imaging Platform technology will be extended across multiple Avalyn studies, whilst the partnership will commence with the ongoing MIST study, a Phase 2b clinical trial evaluating the safety and efficacy of AP01 (inhaled pirfenidone) in patients with progressive pulmonary fibrosis (PPF).